Eduovisual
Female Reproductive & Breast
Ovarian cysts: management of simple and complex
— Reproductive age: Most are functional (follicular, corpus luteum) and resolve spontaneously within 1–3 menstrual cycles.
— Postmenopausal: Any new cyst raises concern for neoplasm; functional cysts should not occur once ovulation has ceased.
— Premenarchal: Rare; raises suspicion for germ cell tumor or precocious puberty workup.
— Asymptomatic adnexal mass on routine bimanual exam or incidental finding on pelvic/abdominal imaging done for another reason.
— Acute pelvic pain (rupture, hemorrhage, torsion) in a reproductive-age woman.
— Chronic pelvic pain, dyspareunia, bloating, early satiety, or urinary frequency (especially concerning for ovarian malignancy in postmenopausal patients).
— Irregular menses, hirsutism, or infertility → polycystic ovary morphology.
— Follicular cyst: Failure of dominant follicle to rupture; typically <8 cm, thin-walled, anechoic.
— Corpus luteum cyst: Failed involution post-ovulation; can hemorrhage and cause acute pain mid-luteal phase.
— Theca lutein cyst: Bilateral, associated with high β-hCG states (molar pregnancy, multiple gestation, ovarian hyperstimulation).
— Endometrioma ("chocolate cyst"), mature teratoma (dermoid), cystadenoma (serous/mucinous), borderline or frank epithelial ovarian cancer.
Board pearl: A simple unilocular cyst <10 cm in a postmenopausal woman with a normal CA-125 has a malignancy risk <1% and can be followed with serial ultrasound rather than surgery — this is the most commonly tested management shift in recent guidelines (ACR O-RADS, ACOG 2016/reaffirmed).
Key distinction: Functional cysts resolve; neoplastic cysts persist beyond two cycles — repeat imaging at 6–12 weeks is the cornerstone of triage.
— Dull, unilateral lower-quadrant ache, worse premenstrually.
— Dyspareunia (deep) — classic for endometrioma or large cyst pressing on cul-de-sac.
— Bloating, early satiety, increased abdominal girth, urinary frequency — the "ovarian cancer symptom index" triad; if present >12 days/month for <1 year in a woman >40, obtain pelvic US and CA-125.
— Cyst rupture: Sudden sharp pain, often post-coital or after exercise; may have peritoneal signs and free fluid; usually self-limited unless hemorrhagic.
— Hemorrhagic corpus luteum: Mid-to-late luteal phase pain, can cause hemoperitoneum; anticoagulated patients at higher risk.
— Ovarian torsion: Sudden severe pain, nausea/vomiting, often intermittent; mass typically >5 cm; surgical emergency.
— LMP timing pinpoints follicular vs. luteal cyst.
— Oligomenorrhea + hirsutism + acne → PCOS phenotype.
— Postmenopausal bleeding with adnexal mass → rule out estrogen-secreting granulosa cell tumor.
— Age >50, postmenopausal status, nulliparity, early menarche/late menopause, BRCA1/2, Lynch syndrome, family history of ovarian/breast/colon cancer, hormone replacement therapy use.
— Protective: Multiparity, breastfeeding, combined OCP use (≥5 years reduces ovarian cancer risk ~50%), tubal ligation, salpingectomy.
Step 3 management: In a reproductive-age woman with new pelvic pain, always pair the history with a urine β-hCG before any imaging or analgesia decision — ectopic pregnancy is the can't-miss mimic and changes the entire algorithm.
— Tachycardia and orthostasis suggest hemoperitoneum from ruptured hemorrhagic cyst or ectopic.
— Fever raises concern for tubo-ovarian abscess rather than uncomplicated cyst.
— Hypotension with rigid abdomen → surgical emergency, mobilize OR.
— Localized tenderness over affected adnexa; rebound and guarding suggest peritoneal irritation from rupture or torsion.
— Distension or shifting dullness raises suspicion for ascites — ominous in postmenopausal patient (malignancy until proven otherwise).
— Palpable mass above pubic symphysis if cyst >12 cm.
— Assess size, mobility, laterality, tenderness, consistency.
— Benign features: Mobile, smooth, unilateral, cystic.
— Concerning features: Fixed, nodular, bilateral, solid, associated with nodularity in cul-de-sac (think endometriosis or peritoneal carcinomatosis).
— Cervical motion tenderness suggests PID/tubo-ovarian abscess, not isolated cyst.
— Adnexal tenderness disproportionate to exam findings.
— Patient writhing rather than lying still (peritonitis patients lie still).
— Nausea and vomiting in ~70%.
— Any palpable ovary is abnormal (ovaries should atrophy to <2 cm and be non-palpable).
— Sister Mary Joseph nodule (umbilical), Virchow node, omental caking on deep palpation — late ovarian cancer.
CCS pearl: On the CCS interface, for a hemodynamically unstable patient with suspected ruptured hemorrhagic cyst, order in parallel: two large-bore IVs, type and crossmatch, CBC, β-hCG, lactate, and bedside transvaginal/transabdominal US — then OB/GYN consult. Do not delay resuscitation for imaging.
Board pearl: A "doughy," tender adnexal mass with chocolate-colored fluid on aspiration = endometrioma; a mobile, non-tender mass with calcifications on imaging = dermoid (mature cystic teratoma).
— Urine or serum β-hCG — rule out pregnancy and ectopic before any other decision.
— CBC — assess for hemorrhage (Hgb drop) or infection (leukocytosis).
— Urinalysis — exclude UTI/stone mimics.
— Type and screen if hemodynamic instability or planned surgery.
— Superior resolution for adnexal characterization compared to CT or MRI.
— Transabdominal added for very large cysts (>10 cm) that extend beyond pelvis.
— Doppler flow assesses vascular pattern (low-resistance flow concerning, absent flow suggests torsion but is unreliable alone).
— Simple cyst: Unilocular, anechoic, thin smooth wall (<3 mm), no solid components, no internal flow, posterior acoustic enhancement.
— Complex cyst: Septations, solid components, papillary projections, mural nodules, internal echoes, ascites, or abnormal Doppler.
— Classic appearances: Endometrioma (homogeneous low-level "ground-glass" echoes), dermoid (hyperechoic with shadowing, Rokitansky nodule, fat-fluid level), hemorrhagic cyst (fishnet/reticular pattern, retracting clot).
— Order in postmenopausal women with any adnexal mass.
— In premenopausal women, CA-125 is nonspecific (elevated in endometriosis, fibroids, PID, pregnancy, menstruation) — use selectively.
— Cutoffs: >35 U/mL postmenopausal triggers gyn-onc referral; premenopausal cutoffs ~200 U/mL more meaningful.
— HE4 — improves specificity; used in ROMA score.
— AFP, LDH, β-hCG, inhibin — germ cell and sex cord-stromal tumors in young women.
— CEA, CA 19-9 — mucinous tumors, exclude GI primary.
Step 3 management: In a postmenopausal woman with any new adnexal mass, the initial workup is transvaginal US plus CA-125 the same visit — both results drive the next branch point (observation vs. gyn-onc referral).
— Best problem-solver when ultrasound is indeterminate.
— Distinguishes endometrioma (T1 hyperintense, T2 shading), dermoid (fat-suppression sequences), fibroma vs. solid neoplasm.
— Preferred in pregnancy when CT undesirable but US insufficient.
— Not first-line for adnexal characterization but essential for staging suspected malignancy: omental caking, peritoneal implants, lymphadenopathy, hepatic metastases, hydronephrosis.
— Useful when acute abdomen is broad differential (appendicitis vs. cyst rupture vs. diverticulitis).
— O-RADS (ACR): Standardized 0–5 risk categories based on US morphology; O-RADS 4–5 → gyn-onc referral.
— RMI (Risk of Malignancy Index): US score × menopausal status × CA-125; RMI >200 → refer.
— ROMA: Combines CA-125 + HE4 + menopausal status.
— Postmenopausal: CA-125 >35, ascites, nodular/fixed mass, suspected metastasis, family history of breast/ovarian cancer.
— Premenopausal: CA-125 >200, ascites, evidence of metastasis, family history.
— Referral improves survival in ovarian cancer — a tested quality-of-care point.
— Do NOT perform percutaneous biopsy or aspiration of a suspicious ovarian mass — risk of malignant seeding and cyst rupture upstaging disease.
— Diagnosis is made surgically via cystectomy or oophorectomy with intraoperative frozen section.
— All women with epithelial ovarian cancer should be offered BRCA1/2 and Lynch syndrome testing regardless of family history.
Board pearl: A postmenopausal woman with a complex adnexal mass and ascites should go directly to gyn-onc — not to general surgery, not to interventional radiology for biopsy. Optimal cytoreduction by a gyn-oncologist is the single strongest modifiable survival factor.
Key distinction: O-RADS 2 (almost certainly benign) → routine follow-up; O-RADS 4–5 → surgical/oncologic evaluation.
— Positive β-hCG → evaluate for ectopic, corpus luteum of pregnancy (normal up to ~16 weeks), or heterotopic pregnancy.
— Premenopausal + simple cyst <5 cm: No follow-up imaging needed; physiologic.
— Premenopausal + simple cyst 5–7 cm: Yearly ultrasound.
— Premenopausal + simple cyst >7 cm: Further imaging (MRI) or surgical evaluation — too large to fully assess sonographically.
— Postmenopausal + simple cyst <1 cm: Clinically inconsequential, no follow-up.
— Postmenopausal + simple cyst 1–7 cm with normal CA-125: Repeat US in 4–6 months, then annually if stable.
— Postmenopausal + simple cyst >7 cm OR rising CA-125: Surgical evaluation.
— Simple, classic features: Observation with serial US.
— Hemorrhagic cyst (premenopausal): Repeat US in 6–12 weeks; most resolve.
— Endometrioma: If <5 cm, asymptomatic → observe; if symptomatic, large, or fertility issues → laparoscopic cystectomy.
— Dermoid: Surgical removal due to torsion/malignant transformation risk (low but real); cystectomy preferred over oophorectomy in reproductive-age women.
— Suspicious/complex features: Surgical exploration with frozen section, gyn-onc involvement.
— Acute severe pain + adnexal mass >5 cm + nausea → suspect torsion → emergent surgery.
— Stable hemorrhagic cyst → outpatient pain control and serial CBC if needed.
Step 3 management: The 2019 ACR O-RADS and SRU consensus shifted toward less surgery for simple cysts — even up to 7 cm in postmenopausal women can be followed if truly simple and CA-125 normal. Old "all postmenopausal cysts come out" teaching is incorrect on current exams.
Board pearl: Combined OCPs do not speed resolution of existing functional cysts but do prevent new ones.
— NSAIDs (ibuprofen 600 mg q6h or naproxen 500 mg BID) — first-line for ruptured cyst pain, hemorrhagic cyst, and dysmenorrhea-associated cyst pain.
— Acetaminophen as adjunct or in NSAID-contraindicated patients (CKD, peptic ulcer, anticoagulation).
— Short opioid courses only for severe breakthrough pain or post-op; avoid chronic use.
— Combined oral contraceptives (COCs): Prevent new functional cysts by suppressing ovulation. Indicated for recurrent functional cysts and for endometriosis-associated cyst pain.
— COCs do not shrink existing cysts — counsel accordingly.
— Progestin-only options (depot medroxyprogesterone, levonorgestrel IUD) for women with COC contraindications (smokers >35, migraine with aura, VTE history).
— NSAIDs first-line for pain.
— Continuous COCs, progestins, or GnRH agonists (leuprolide) for refractory symptoms — typically used 3–6 months with add-back therapy to prevent bone loss.
— Medical therapy does not eliminate the cyst; surgical excision is required for definitive removal and fertility benefit.
— Combined OCPs for cycle regulation, hirsutism, endometrial protection.
— Metformin for insulin resistance/glucose intolerance.
— Letrozole first-line for ovulation induction if pregnancy desired.
— Review anticoagulation indication and intensity; consider dose reduction or hold if active bleeding.
— Reverse warfarin with vitamin K ± PCC if hemodynamically significant hemorrhage; reverse DOACs with andexanet/idarucizumab as appropriate.
Board pearl: A woman on chronic warfarin with recurrent hemorrhagic ovarian cysts is a classic vignette — management is ovulation suppression with COCs or progestin to prevent corpus luteum formation, not stopping anticoagulation if indication remains.
Key distinction: COCs prevent new functional cysts; they do not shrink existing ones — high-yield trap.
— Less pain, faster recovery, fewer adhesions vs. laparotomy.
— Ovarian cystectomy preserves ovarian tissue and fertility — preferred in reproductive-age women.
— Oophorectomy/salpingo-oophorectomy for postmenopausal women, suspected malignancy, or severely damaged ovary.
— Cyst >10 cm (high torsion risk regardless of features).
— Persistent cyst >12 weeks not consistent with functional cyst.
— Suspicious morphology (O-RADS 4–5).
— Acute torsion or significant hemoperitoneum.
— Symptomatic dermoid or endometrioma.
— Detorsion with ovarian conservation is now standard, even with apparent necrotic appearance — most ovaries recover function.
— Old teaching of automatic oophorectomy due to "thromboembolism risk" is outdated; current data show no increased VTE.
— Oophoropexy may be considered for recurrent torsion or congenitally long utero-ovarian ligaments.
— Vertical midline laparotomy (better staging access) — though laparoscopic staging by experienced gyn-onc is acceptable for early disease.
— Peritoneal washings, careful inspection, frozen section.
— Complete staging: TAH-BSO, omentectomy, pelvic/para-aortic lymphadenectomy, appendectomy (mucinous tumors).
— Avoid intraoperative cyst rupture — upstages disease and worsens prognosis.
CCS pearl: For suspected ovarian torsion, the order set is: NPO, IV fluids, IV analgesia, antiemetics, CBC/type and screen, urgent transvaginal US with Doppler, gyn consult, OR booking — clock starts immediately. Ovarian salvage rates fall sharply after 24–48 hours.
Step 3 management: Refer all suspected ovarian cancers to a gynecologic oncologist preoperatively — optimal cytoreduction improves survival by 10+ months.
— Any new adnexal mass is abnormal but not automatically malignant; modern data show ~85% of simple cysts in postmenopausal women are benign serous cystadenomas or inclusion cysts.
— Risk of malignancy increases with: increasing age, complex morphology, rising CA-125, family history of BRCA/Lynch.
— Hormone replacement therapy can occasionally cause persistent functional-appearing cysts.
— Preoperative cardiac evaluation per AHA/ACC (functional capacity, RCRI).
— Frailty index correlates better with outcomes than chronologic age.
— Consider minimally invasive approach when feasible; expedites return to baseline.
— VTE prophylaxis essential — older women with gynecologic surgery + possible malignancy are high-risk (mechanical + pharmacologic).
— Avoid NSAIDs in eGFR <30 or AKI — use acetaminophen for pain control.
— Contrast imaging (CT, MRI gadolinium) — assess eGFR; gadolinium contraindicated when eGFR <30 due to NSF risk (group I/II agents now lower risk).
— Renally adjust prophylactic enoxaparin to 30 mg daily if CrCl <30.
— CA-125 can be falsely elevated in renal failure.
— CA-125 elevated in cirrhosis with ascites — reduces specificity dramatically.
— Coagulopathy may complicate surgical planning; correct INR, transfuse platelets as needed.
— Acetaminophen ≤2 g/day in significant liver disease.
— Higher rate of hemorrhagic cysts and intracystic hemorrhage mimicking complexity.
— Repeat imaging after a cycle (if still cycling) or after 6–12 weeks may clarify; hemorrhagic features should evolve/resolve.
Board pearl: Cirrhotic ascites + elevated CA-125 + small adnexal cyst is a classic mimic for ovarian malignancy — paracentesis cytology and HE4 (less affected by liver disease) help distinguish.
Step 3 management: In the postmenopausal woman, do not skip the CA-125 just because the cyst looks simple — combination determines whether observation is truly safe.
— Corpus luteum of pregnancy: Normal finding through ~10–16 weeks; supports pregnancy via progesterone; usually <5 cm, may be up to 10 cm.
— Theca lutein cysts: Bilateral, multiseptated, associated with high β-hCG (molar pregnancy, multiple gestation, ovarian hyperstimulation syndrome). Regress after delivery/treatment.
— Hyperreactio luteinalis: Pregnancy-associated bilateral cystic enlargement; conservative management.
— Most resolve by 16 weeks; observe simple cysts <6 cm.
— Persistent or complex masses → MRI without gadolinium preferred for characterization.
— Surgery, if needed, ideally performed in second trimester (16–20 weeks) — organogenesis complete, reduced miscarriage risk, uterus not yet too large.
— Emergent surgery (torsion, malignancy) — perform regardless of trimester.
— Tumor markers unreliable in pregnancy: AFP, β-hCG, CA-125, inhibin all physiologically elevated.
— Increased risk due to enlarged ovaries (especially after ovulation induction).
— Most common in first trimester.
— Detorsion with cyst preservation is preferred approach.
— Neonatal cysts: maternal hormone-driven, regress spontaneously over weeks-months; surgery only if >5 cm or complex.
— Premenarchal cyst: workup for germ cell tumor with AFP, β-hCG, LDH, inhibin.
— Adolescent ovarian torsion: cyst size >5 cm, sudden pain, vomiting — always favor ovarian-sparing surgery, even with necrotic appearance.
— Mature cystic teratoma is most common adnexal neoplasm in adolescents.
— Iatrogenic from fertility treatments; bilateral enlarged multi-cystic ovaries with ascites, electrolyte imbalance, hypercoagulability.
— Severe cases: hospitalization, IV fluids, albumin, paracentesis, VTE prophylaxis.
Key distinction: A simple cyst in pregnancy = likely corpus luteum if first-trimester; in a neonate = maternal hormones; in a premenarchal child = workup for germ cell tumor.
Board pearl: Elective adnexal surgery in pregnancy is timed to 16–20 weeks; emergencies cannot wait.
— Most are self-limited; pain managed with NSAIDs and observation.
— Hemorrhagic rupture can cause significant hemoperitoneum; rare but classic in anticoagulated patients or large corpus luteum cysts.
— Severe cases: hemodynamic instability requiring transfusion and surgical hemostasis.
— Cyst >5 cm is the strongest risk factor; dermoids especially due to weight.
— Ischemic necrosis if unrecognized → permanent loss of ovarian function, reduced fertility.
— Bilateral torsion (rare) can cause complete loss of reproductive function.
— Recurrence rate after detorsion ~5–10% — consider oophoropexy in recurrent cases.
— Endometriomas: rare malignant transformation (<1%) to clear cell or endometrioid ovarian cancer, especially in postmenopausal women with persistent endometriomas.
— Mature cystic teratomas: ~1–2% malignant transformation, usually squamous cell carcinoma, in women >40 with large dermoids (>10 cm).
— Bleeding, infection, injury to bowel/bladder/ureter.
— Adhesion formation affecting future fertility.
— Reduced ovarian reserve after cystectomy — particularly with endometriomas (loss of normal ovarian cortex with cyst wall).
— Surgical menopause if bilateral oophorectomy in premenopausal woman → vasomotor symptoms, bone loss, cardiovascular risk.
— Recurrent endometriomas reduce ovarian reserve.
— Aggressive cystectomy can damage normal ovary; balance symptom relief vs. reserve preservation.
— Counsel about oocyte cryopreservation before surgery in young women with bilateral disease.
— Ascites, bowel obstruction, malnutrition, VTE (Trousseau-like syndrome), paraneoplastic phenomena.
Board pearl: A woman with prior cystectomy for "ovarian cyst" who later develops ovarian cancer often had a borderline tumor incompletely excised — emphasizes importance of intraoperative frozen section and gyn-onc involvement when features are concerning.
Step 3 management: Counsel all premenopausal patients before adnexal surgery about fertility implications and consider reproductive endocrinology referral if bilateral pathology.
— Suspected ovarian torsion — clock starts at presentation; salvage rates fall after 24–48 hours.
— Ruptured hemorrhagic cyst with hemodynamic instability or large hemoperitoneum.
— Acute abdomen with peritoneal signs.
— Suspected ruptured ectopic pregnancy (always part of differential).
— Persistent symptomatic cysts not responding to medical management.
— Large cysts (>10 cm) at high torsion risk.
— Suspected dermoid or symptomatic endometrioma.
— Postmenopausal: CA-125 >35 U/mL, nodular/fixed mass, ascites, complex morphology on imaging, evidence of metastasis, family history of breast/ovarian cancer.
— Premenopausal: CA-125 >200 U/mL, ascites, evidence of metastasis, family history.
— Refer before surgery — pre-operative referral improves optimal cytoreduction rates and survival.
— Severe OHSS with respiratory compromise, renal failure, or thromboembolism.
— Massive hemoperitoneum with ongoing transfusion requirements.
— Sepsis from tubo-ovarian abscess (alternative diagnosis).
— Stable hemorrhagic cyst → outpatient management with NSAIDs, return precautions.
— Severe pain requiring IV opioids, intractable nausea → short admission.
— Suspected torsion → admission and emergent OR.
— Document size, morphology, CA-125, and recommended follow-up imaging interval at discharge.
— Communicate with primary care and outpatient gynecology for imaging continuity.
— Provide written return precautions: severe pain, fever, syncope, persistent vomiting.
CCS pearl: In CCS, transition the unstable hemorrhagic cyst patient through ED → resuscitation → OR; for stable cases, advance the simulated clock through observation and reassess vitals/Hgb at 4–6 hours before discharge.
Key distinction: Any postmenopausal patient with adnexal mass + ascites bypasses general gynecology and goes directly to gyn-onc.
— Fever, leukocytosis, cervical motion tenderness, recent or current PID, vaginal discharge.
— US shows complex multiloculated adnexal mass with thick walls.
— Treatment: IV antibiotics (cefoxitin + doxycycline or ampicillin-sulbactam + doxycycline ± metronidazole); drainage if >7 cm or no response in 48–72 hours.
— Positive β-hCG, adnexal mass, abdominal pain ± vaginal bleeding.
— β-hCG plateaus or rises abnormally; discriminatory zone ~3500 mIU/mL — no IUP visible → suspect ectopic.
— Treatment: methotrexate vs. surgery based on stability and criteria.
— Tubular fluid-filled adnexal structure on US; often associated with PID history or endometriosis.
— Hydrosalpinx significantly reduces IVF success and warrants salpingectomy before fertility treatment.
— Mesothelial-origin cyst adjacent to ovary, often discovered incidentally.
— Simple cysts can be observed; surgical removal if symptomatic or large.
— Solid ovarian mass, can mimic complex cyst.
— Meigs syndrome: Benign ovarian fibroma + ascites + right pleural effusion (resolves after tumor removal).
— Homogeneous low-level "ground-glass" echoes on US; T1 hyperintense, T2 shading on MRI.
— Associated with infertility, dyspareunia, dysmenorrhea.
— Hyperechoic with shadowing, Rokitansky nodule, fat-fluid levels; calcifications on CT/x-ray.
— Surgical removal recommended due to torsion risk and rare malignant transformation.
— Imaging mimics cystadenoma; papillary projections, septations; younger women.
— Treatment is surgical; conservative for fertility preservation possible.
Board pearl: Right-sided pleural effusion + ascites + solid ovarian mass → Meigs syndrome; left-sided supraclavicular lymphadenopathy (Virchow) + adnexal mass → metastatic cancer (often GI Krukenberg vs. ovarian primary).
Key distinction: Hydrosalpinx is tubular; ovarian cyst is round — shape on US is diagnostic.
— Appendicitis: Right lower quadrant pain, fever, leukocytosis; can mimic right ovarian pathology. Imaging (US then CT) differentiates.
— Diverticulitis: Left lower quadrant pain, fever; in older women, can mimic left adnexal pathology.
— Inflammatory bowel disease: Crohn's terminal ileitis can cause RLQ mass and pain.
— Mesenteric/peritoneal cysts: Rare, large fluid collections that can be mistaken for ovarian cysts on imaging.
— Ureteral stone: Colicky flank-to-groin pain, hematuria; CT or US identifies.
— Bladder diverticulum or urachal cyst: Midline pelvic structures, occasional confusion.
— Pelvic kidney: Can present as palpable pelvic mass; cross-sectional imaging clarifies.
— Ovarian vein thrombosis: Postpartum or postoperative, right-sided RLQ pain, fever; diagnosis by CT/MRI.
— Aortic/iliac aneurysm: Rare in younger women but consider in older patients with pulsatile masses.
— Krukenberg tumor: Bilateral ovarian metastases from GI (gastric > colorectal) or breast primary. Signet-ring cells on histology.
— Always consider primary GI/breast workup when bilateral ovarian masses are present (mammography, colonoscopy, upper endoscopy as appropriate).
— PCOS: Polycystic ovary morphology (≥12 follicles 2–9 mm per ovary or volume >10 mL), not "cysts" requiring surgery.
— Pelvic congestion syndrome: Dilated pelvic veins, chronic pelvic pain worse with standing.
— Lymphoma, sarcoma, schwannoma — can present as pelvic masses.
Board pearl: Bilateral solid ovarian masses with signet-ring cells = Krukenberg — always pursue GI primary (upper endoscopy and colonoscopy) before assuming ovarian origin.
Step 3 management: In any woman over 50 with a new adnexal mass and GI symptoms (weight loss, anemia, change in bowel habits), include colonoscopy and upper endoscopy in workup before adnexal surgery.
— Combined oral contraceptives suppress ovulation and prevent new follicular/corpus luteum cysts. Indicated for recurrent symptomatic functional cysts.
— Continuous COCs (no placebo week) may further reduce cyst formation.
— Alternative: contraceptive patch, ring, or progestin-only methods (depot, implant, LNG-IUD) for women with COC contraindications.
— Post-cystectomy hormonal suppression (COCs, progestins, GnRH agonists) reduces recurrence by ~50%.
— Continue until pregnancy is desired or definitive surgery performed.
— Combined OCPs ≥5 years: ~50% reduction in lifetime ovarian cancer risk; benefit persists 30 years after cessation.
— Tubal ligation and bilateral salpingectomy: Reduce ovarian cancer risk, particularly for high-grade serous tumors thought to originate in fallopian tube.
— Opportunistic salpingectomy at time of hysterectomy or sterilization is now recommended for women who have completed childbearing.
— Risk-reducing salpingo-oophorectomy (RRSO): Recommended for BRCA1 mutation carriers at age 35–40 and BRCA2 carriers at 40–45 after childbearing complete.
— Personal or family history of ovarian, breast (especially premenopausal), endometrial, or colon cancer.
— Ashkenazi Jewish heritage with relevant family history.
— All women diagnosed with epithelial ovarian cancer should be offered germline testing.
— Pain control plan with NSAIDs ± short opioid course.
— VTE prophylaxis (mechanical, ambulation; pharmacologic if malignancy).
— Hormonal suppression if indicated (endometriosis, PCOS).
— Iron supplementation if anemic.
— Return precautions and follow-up appointment.
Board pearl: Five-plus years of combined OCPs reduces ovarian cancer risk by ~50% — among the most exam-tested protective associations in gynecology.
Step 3 management: Counsel BRCA1/2 carriers about RRSO timing — surgery prevents ovarian cancer but causes surgical menopause; weigh hormone replacement therapy options post-procedure.
— Premenopausal simple cyst <5 cm: No follow-up.
— Premenopausal simple cyst 5–7 cm: Annual ultrasound.
— Premenopausal hemorrhagic cyst <5 cm: No follow-up. 5–7 cm: short-interval US in 6–12 weeks.
— Premenopausal endometrioma or dermoid: Annual US if managed nonoperatively.
— Postmenopausal simple cyst <1 cm: No follow-up.
— Postmenopausal simple cyst 1–7 cm: US in 1 year (or 4–6 months initially, then annual if stable).
— Postmenopausal cyst >7 cm or any complex features: MRI or surgical evaluation.
— Not used for screening in asymptomatic average-risk women (poor specificity).
— Trend post-operatively in known epithelial ovarian cancer for response/recurrence.
— Single elevated value in surveillance without symptoms or imaging change does not mandate immediate retreatment — confirm with imaging.
— Educate patients on torsion red flags: sudden severe unilateral pain, persistent nausea/vomiting — return immediately.
— Hemorrhagic cyst pain typically peaks in 24–48 hours and resolves over days.
— Laparoscopic cystectomy: return to light activity in 1–2 weeks; avoid heavy lifting 4–6 weeks.
— Sexual activity typically resumed in 2–4 weeks.
— Wound care, signs of infection education.
— Discuss ovarian reserve testing (AMH, AFC) after bilateral endometrioma surgery.
— Reproductive endocrinology referral if planning pregnancy with reduced reserve.
— Anxiety about cancer concerns is common; provide clear reassurance backed by imaging and labs.
— Chronic pelvic pain patients benefit from multidisciplinary approach (pain specialist, physical therapy, mental health support).
Step 3 management: Schedule postoperative gyn follow-up at 2–6 weeks; ensure pathology results are reviewed in person, especially if frozen section was concerning.
CCS pearl: Always advance the CCS clock to confirm symptom resolution and review repeat imaging before closing the case for a cyst patient.
— Risks include bleeding, infection, injury to bowel/bladder/ureter, conversion to laparotomy, need for oophorectomy if cyst cannot be salvaged, impact on fertility.
— Discuss possibility of finding malignancy intraoperatively and predetermined plan (frozen section, staging laparotomy, gyn-onc involvement).
— In reproductive-age women, explicit consent for ovarian conservation vs. oophorectomy is critical — document patient preferences clearly.
— Offer oocyte/embryo cryopreservation referral before surgery when bilateral disease, high recurrence risk, or known reduced reserve.
— Document that fertility implications were discussed.
— Most states allow minors to consent for reproductive healthcare, but ovarian surgery generally requires parental consent except in emergencies.
— Confidentiality concerns when parents are involved; balance privacy with safety.
— Missed follow-up imaging is a common malpractice issue — close the loop with a documented follow-up appointment and patient understanding.
— Inadequate communication between ED, gynecology, and primary care can delay diagnosis of borderline or early malignancy.
— Use electronic health record reminders for serial imaging in observed cysts.
— Failure to obtain CA-125 with adnexal mass in postmenopausal women has been cited in litigation; document rationale if omitted.
— Failure to refer to gyn-onc when criteria met is a known patient safety gap.
— Discuss implications for family members; GINA protections (US) prevent insurance discrimination based on genetic information.
— Document offer of BRCA/Lynch testing for ovarian cancer patients.
— Respect patient preferences about ovarian preservation, hormonal therapy, and reproductive choices.
— Use interpreters when language barriers exist; document.
Board pearl: The most common Step 3 ethics scenario for ovarian cysts is the transition-of-care lapse — a postmenopausal woman discharged after ED visit for "ovarian cyst" without scheduled gyn follow-up who later presents with advanced ovarian cancer. Closed-loop communication is the protective practice.
Board pearl: The single most tested management shift in recent years: postmenopausal simple cysts no longer require automatic surgery — observation with serial US and CA-125 is appropriate when criteria met.
— 28-year-old with incidental 4 cm simple cyst on US ordered for dysuria. β-hCG negative.
— Answer: Reassurance, no follow-up needed (or repeat US in 6–12 weeks if symptomatic).
— Trap: Ordering CA-125 (not indicated in young woman with classic functional cyst).
— 62-year-old with bloating, weight loss, 8 cm complex adnexal mass with septations and solid components, ascites, CA-125 480 U/mL.
— Answer: Referral to gynecologic oncologist for surgical staging.
— Trap: Image-guided biopsy (contraindicated — risk of seeding).
— 24-year-old with sudden severe right lower quadrant pain, nausea, vomiting; US shows 7 cm dermoid with reduced/absent Doppler flow.
— Answer: Emergent laparoscopy with detorsion and ovarian preservation.
— Trap: Choosing oophorectomy because ovary "looks dusky."
— 35-year-old on warfarin for mechanical valve with acute pelvic pain, US shows 5 cm cyst with internal echoes and reticular pattern.
— Answer: Supportive care, repeat US in 6–12 weeks; consider COCs for prevention (do NOT stop anticoagulation).
— 22-year-old at 9 weeks with 6 cm simple cyst.
— Answer: Repeat US at 14–16 weeks (likely corpus luteum, expect resolution).
— Trap: Immediate surgery (delay to second trimester or longer if simple).
— Answer: Workup for GI primary (upper endoscopy, colonoscopy) — Krukenberg tumor.
— Solid ovarian mass + right pleural effusion + ascites with negative cytology.
— Answer: Surgical removal of ovarian fibroma; effusion and ascites resolve.
— 38-year-old BRCA1 carrier asking about cancer prevention.
— Answer: Risk-reducing salpingo-oophorectomy at age 35–40.
— Postmenopausal bleeding + adnexal mass + endometrial hyperplasia on biopsy.
— Answer: Surgical removal; consider inhibin as marker.
Step 3 management: Pay close attention to menopausal status and CA-125 — these two pieces of information drive almost every ovarian cyst question's correct branch point.
Ovarian cyst management hinges on three questions: Is she pregnant? What's her menopausal status? And does the cyst look simple or complex on transvaginal ultrasound — because the answers determine whether you observe, suppress with hormones, or operate (and with whom).
Board pearl: The trio of menopausal status, ultrasound morphology, and CA-125 is the Step 3 algorithm — master those three inputs and nearly every ovarian cyst question becomes a structured decision tree rather than a guess.